Targeting Pathological Tau Epitopes for Alzheimer's Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for Alzheimer's disease and tauopathies lack high target specificity and safety in clearing neurofibrillary tangles and pathological tau conformers, leading to potential toxicity and ineffective treatment outcomes.
Innovation Solution
Administration of immunogenic tau peptides or antibodies that recognize specific phospho-epitopes of pathological tau, inducing a targeted immune response to clear tau aggregates while minimizing adverse effects on normal tau protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy is used to clear tau aggregates, then treatment efficacy is improved, but target specificity and safety deteriorate due to potential toxicity to normal tau protein
Solution Approach 1:
The patent targets specific phosphorylated epitopes (local regions) of tau protein that are pathologically modified, rather than the entire tau protein. By designing antibodies and peptides that recognize only the phosphorylated forms at specific sites, the therapy achieves local specificity - attacking only the harmful phosphorylated regions while leaving normal unphosphorylated tau intact.
Solution Approach 2:
The invention exploits the chemical parameter change of phosphorylation to differentiate pathological tau from normal tau. By targeting the phosphorylated state (a modified chemical parameter) rather than the base tau structure, the therapy can selectively recognize and clear pathological conformers while preserving normal tau function.
2Adaptability or versatility
If broad-spectrum immunotherapy is used to clear tau aggregates, then treatment coverage is improved, but safety deteriorates due to lack of target specificity
Solution Approach 1:
The patent employs multiple antibodies and peptides targeting different phosphorylated epitopes throughout the tau protein sequence. Each component has localized specificity for particular phosphorylation sites, but the combination provides broad coverage of pathological tau forms while maintaining individual component safety through localized targeting.
Solution Approach 2:
The invention uses composite immunotherapeutic approaches combining multiple antibodies and peptides with different specificities. This composite strategy achieves both broad treatment coverage (by targeting multiple sites) and high safety (by using individual components with localized specificity that minimize off-target effects).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach achieves robust immune response against pathological tau with enhanced specificity and safety, effectively reducing tau pathology and slowing disease progression in animal models, as demonstrated by significant reduction in tau aggregates and improved cognitive functions.
Implementation Method 1
Administration of immunogenic tau peptides or antibodies that recognize specific phospho-epitopes of pathological tau, inducing a targeted immune response to clear tau aggregates
Data Source
AI summary
The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.